PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.

Abstract

The DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP-1) is overexpressed in glioblastoma, with overall low expression in healthy brain tissue. Paired with the availability of specific small molecule inhibitors, PARP-1 is a near-ideal target to develop novel radiotherapeutics to induce DNA damage and apoptosis in cancer cells, while sparing healthy brain tissue. <b>Methods:</b> We synthesized an ¹³¹I-labeled PARP-1 therapeutic and investigated its pharmacology in vitro and in vivo. A subcutaneous tumor model was used to quantify retention times and therapeutic efficacy. A potential clinical scenario, intratumoral convection-enhanced delivery, was mimicked using an orthotopic glioblastoma model combined with an implanted osmotic pump system to study local administration of ¹³¹I-PARPi (PARPi is PARP inhibitor). <b>Results:</b>¹³¹I-PARPi is a 1(2H)-phthalazinone, similar in structure to the Food and Drug Administration-approved PARP inhibitor AZD-2281. In vitro studies have shown that ¹³¹I-PARPi and AZD-2281 share similar pharmacologic profiles. ¹³¹I-PARPi delivered 134.1 cGy/MBq intratumoral injected activity. Doses to nontarget tissues, including liver and kidney, were significantly lower. Radiation damage and cell death in treated tumors were shown by p53 activation in U87-MG cells transfected with a p53-bioluminescent reporter. Treated mice showed significantly longer survival than mice receiving vehicle (29 vs. 22 d, <i>P</i> < 0.005) in a subcutaneous model. Convection-enhanced delivery demonstrated efficient retention of ¹³¹I-PARPi in orthotopic brain tumors, while quickly clearing from healthy brain tissue. <b>Conclusion:</b> Our results demonstrate ¹³¹I-PARPi's high potential as a therapeutic and highlight PARP's relevance as a target for radionuclide therapy. Radiation plays an integral role in brain tumor therapy, and radiolabeled PARP therapeutics could ultimately lead to improvements in the standard of care.